Kar9 inhibitors belong to a class of chemical compounds that have gained significant attention in the field of molecular biology and cell biology. These inhibitors are specifically designed to target the Kar9 protein, which plays a pivotal role in the regulation of cellular processes, particularly in yeast cells. Kar9 is a microtubule-binding protein that is crucial for the proper positioning of the mitotic spindle during cell division in yeast. This process is essential for ensuring the accurate distribution of genetic material into the daughter cells. Kar9 inhibitors, as the name suggests, are molecules that can selectively interfere with the function of the Kar9 protein, thereby influencing the dynamics of microtubules and spindle positioning within the cell.
The mechanism of action of Kar9 inhibitors typically involves binding to specific sites on the Kar9 protein, disrupting its normal interactions with microtubules and other cellular components. By doing so, these inhibitors can lead to aberrant spindle positioning, which can result in cell cycle defects and ultimately impact cell division. Researchers have used Kar9 inhibitors as valuable tools to investigate the molecular mechanisms underlying spindle positioning and cell division in yeast cells. They provide a means to study the intricate network of protein interactions and signaling pathways involved in these processes. Additionally, the development of Kar9 inhibitors has implications for understanding similar microtubule-based processes in other organisms, shedding light on fundamental aspects of cell biology beyond yeast cells.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets the BCR-ABL tyrosine kinase, inhibiting its activity, commonly used for myeloid leukemia (CML) and certain types of tumors. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR inhibitor that blocks signaling pathways involved in cell growth, used in non-small cell lung cancer (NSCLC). | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases including Raf and VEGFR, used for advanced kidney and liver cancers. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual inhibitor of EGFR and HER2, used for HER2-positive breast cancer | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Targets multiple tyrosine kinases, including BCR-ABL and SRC, used for CML and acute lymphoblastic leukemia (ALL). | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Inhibits multiple receptor tyrosine kinases (RTKs) including VEGFR, PDGFR, and others, used for renal cell carcinoma (RCC) and other cancers. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
EGFR inhibitor used in NSCLC by blocking the signaling pathways that promote cancer cell growth. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Targets BCR-ABL and other kinases, used for CML and Philadelphia chromosome-positive ALL. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Inhibits multiple kinases including VEGFR, PDGFR, and FGFR, used in idiopathic pulmonary fibrosis (IPF) and certain cancers. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly inhibits BTK (Bruton's tyrosine kinase), used for B-cell malignancies such as CLL and mantle cell lymphoma. | ||||||